Main Uses and Benefits of Sincalide

Sincalide is a synthetic hormone used primarily as a diagnostic aid to evaluate the function of the gallbladder and pancreas. It works by mimicking the effects of cholecystokinin, a naturally occurring hormone in the body that signals the digestive system to release bile and enzymes.

Gallbladder Function Testing

The primary use of sincalide is to stimulate gallbladder contraction. This allows healthcare professionals to measure the gallbladder ejection fraction, which is the percentage of bile pumped out of the gallbladder during contraction. This procedure is helpful in diagnosing several conditions:

• Chronic Cholecystitis: By assessing how well the gallbladder empties, clinicians can identify chronic inflammation or dysfunction.
• Biliary Dyskinesia: This is a condition where the gallbladder does not contract properly, even in the absence of gallstones.
• Gallstone Evaluation: It can help determine if gallstones are causing a functional blockage or if the gallbladder is operating normally despite their presence.

Pancreatic Function Testing

Sincalide is also utilized to evaluate the exocrine function of the pancreas. When administered in conjunction with other diagnostic agents, it stimulates the pancreas to secrete digestive enzymes and bicarbonate. This application is beneficial for:

• Assessing Pancreatic Insufficiency: Helping to determine if the pancreas is producing enough enzymes to properly digest food.
• Diagnostic Imaging: It can be used to improve the visualization of the pancreatic duct during certain imaging procedures.

Acceleration of Biliary Transit

In certain diagnostic imaging scenarios, such as a hepatobiliary (HIDA) scan, sincalide may be used to speed up the movement of bile through the system. This can reduce the time required for the test by accelerating the transit of radiopharmaceuticals from the liver into the gallbladder and small intestine, providing clearer results in a shorter timeframe.

Regulatory References

1. NIH DailyMed Drug Labeling

The eligibility profile for using Sincalide is strictly defined by regulatory guidelines focused on patient characteristics and pre-existing conditions, ensuring appropriate use of this diagnostic agent.

Contraindicated Populations (Prohibited Use)

Sincalide is contraindicated in patients with a known history of hypersensitivity to sincalide or sulfites. Use is also strictly prohibited in patients diagnosed with intestinal obstruction.

Age-Based and Reproductive Status

Conditions for Conditional Use

Special consideration is required for patients with small gallbladder stones. Gallbladder contraction induced by Sincalide may cause the stones to evacuate and potentially lodge in the bile ducts. Use is also restricted in clinical situations where inducing gallbladder contraction is medically unsuitable, such as in cases of acute pancreatitis or acute cholecystitis, as defined in regulatory monographs.

The official regulatory profile for Sincalide interactions centers on pharmacodynamic effects that could interfere with the intended diagnostic test result, rather than complex pharmacokinetic drug-drug interactions.

Interaction Scope

Official Interaction Statements

• Co-administration with Secretin results in a pharmacodynamic reinforcement that increases the volume and output of bicarbonate and protein in pancreatic secretion for diagnostic purposes.
• Substances that affect gallbladder motility may interfere with the expected diagnostic response to Sincalide. This interference can result in a false diagnostic outcome.
• Consumption of food, particularly high-fat meals, must be restricted before administration because it triggers the release of endogenous CCK, which interferes with the intended diagnostic outcome.

The regulatory documents establish that the product's interaction structure is dominated by pharmacodynamic effects related to its use as a diagnostic agent, not by typical metabolic or pharmacokinetic interactions. This profile defines conditions necessary to prevent procedural interference from co-administered medicines or the body's natural response to food.

Sincalide, a synthetic analog of cholecystokinin (CCK-8), acts as an agonist that specifically binds to the cholecystokinin-A (CCK-A) receptors. These G-protein coupled receptors are situated on the smooth muscle of the gallbladder and the sphincter of Oddi. Receptor activation triggers an intracellular second messenger cascade, primarily involving the activation of phospholipase C and the subsequent release of calcium (Ca^2+) from internal stores. This calcium-mediated pathway leads directly to the activation of contractile proteins within the affected smooth muscle cells. The ultimate physiological consequence is the contraction of the gallbladder and a concurrent relaxation of the sphincter of Oddi, increasing intraluminal pressure. This dual action facilitates the controlled expulsion of bile and pancreatic fluid into the duodenum, modulating the movement of gastrointestinal contents.

Official Administration Guidelines

Sincalide is used strictly as a diagnostic tool, and its administration follows a highly structured protocol. It is supplied as a lyophilized powder for injection and must be reconstituted and administered via the intravenous (IV) route. It is not administered orally.

Preparation and Administration Specifics

Proper use requires specific steps to ensure drug integrity and accurate delivery. The 5 mcg vial must be reconstituted aseptically by adding 5 mL of Sterile Water for Injection USP. For use in a slow IV infusion, the resulting solution must be further diluted with 0.9% Sodium Chloride Injection USP. The specific rate of administration varies by indication, such as a rapid bolus over 30 to 60 seconds or a slow infusion over 30 to 50 minutes.

Population Use Boundaries

Regarding specific populations, the safety and effectiveness of Sincalide have not been established for use in pediatric patients (under 18 years of age). Data for dose adjustments in patients with renal or hepatic impairment are not available.

These instructions establish a non-therapeutic, standardized, and acute administration protocol, governing its use from preparation to final delivery within a supervised setting.

Research evidence / Overview of studies for Sincalide

Evidence for use in Gallbladder Function Assessment

Research has explored methods used to measure the functional ability of the gallbladder to contract. Studies explored this using controlled clinical trials and multicenter investigations. The research examined outcomes related to systemic or functional imbalance, specifically focusing on the Gallbladder Ejection Fraction (GBEF). The data collected was relevant in trials assessing short-term or episodic symptom patterns in adults who were being evaluated for possible biliary issues.

Findings describe patterns observed in the studies, reporting measurements of maximal gallbladder contraction during the diagnostic procedure. Research also highlights changes measured during the study period related to differing methods of administering the agent, such as the rate of infusion. Early evidence contributes to understanding symptom patterns by tracking the relationship between the GBEF measurement and patient-reported outcomes describing perceived discomfort in the studies that evaluated patients after certain procedures.

However, certainty remains low regarding the consistent prediction of patient-reported outcomes. Comparative evidence is lacking on how consistently the measurement can be reproduced across different testing centers. Furthermore, research provides context but not individual predictions, meaning that the results apply only to the populations studied and long-term outcomes are not fully established.

Evidence for use in Pancreatic Secretory Function Assessment

Sincalide was evaluated in observational settings evaluating daily-life functioning as part of a classic two-step diagnostic procedure involving Secretin. This research examined outcomes related to systemic or functional imbalance, focusing on measuring the body's acute response to stimulation. The studies explored the resulting volume and specific enzyme content of fluid secreted by the pancreas.

Studies focusing on episodes where symptoms become more noticeable used this agent to facilitate the process of obtaining these samples. Research describes the resulting documentation of the pancreatic physiological response, and research documented the agent’s role in the procedural evaluation. The findings help contextualize how patients reported their experience by providing objective information about the underlying condition marked by functional limitations.

Evidence in Special Populations

Data for certain groups remain insufficient to draw conclusions, particularly for pregnant populations or those with significant co-existing functional disorders. A specialized area of research involving severely premature neonates was conducted, and the agent was evaluated in this specific, vulnerable cohort. The research explored outcomes related to bilirubin and bile acid levels in this group. The outcomes for this particular use are not fully established, and this remains an investigational context. The results apply only to the populations studied, and the evidence derived from settings with varying symptom burdens in this cohort may not be generalized.

Key Studies & References

1. CCK-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel (Review/Guideline)
2. Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis (ClinicalTrials.gov ID NCT00004414)

How to Store and Dispose of Sincalide?

The Sincalide lyophilized powder must be stored at Controlled Room Temperature (CRT), which is defined as 20 C to 25 C (68 F to 77 F). The powder should be protected from excessive heat.

Stability After Preparation

Sincalide is supplied as a preservative-free, single-dose vial. Strict time limits apply once the powder is reconstituted:

• For Intravenous Injection: The solution must be discarded after 8 hours if stored at room temperature.
• For Intravenous Infusion: The diluted solution must be discarded after 1 hour if stored at room temperature.

Disposal and Safety

This product is for single use only; any unused portion must be discarded. Disposal of unused product and waste material must be carried out according to institutional and local requirements. As with all medications, Sincalide must be kept out of the sight and reach of children.